Sanofi’s Phase 3 Study on Belumosudil for CLAD: A Potential Game-Changer

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.

Sanofi is conducting a Phase 3 study titled A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation. The study aims to assess the efficacy and safety of Belumosudil tablets in treating adults with CLAD, a significant condition affecting lung transplant recipients.

The study tests Belumosudil, an oral tablet, in combination with Azithromycin, against a placebo. The goal is to determine if Belumosudil can effectively manage CLAD symptoms when added to standard immunosuppression therapy.

This interventional study follows a randomized, parallel-group design with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary aim is to evaluate treatment efficacy.

The study began on October 10, 2023, and is currently recruiting participants. The primary completion date is anticipated in 2025, with the last update submitted on August 12, 2025. These dates are crucial for tracking progress and anticipating results.

The study’s outcome could significantly impact Sanofi’s stock performance, as successful results may enhance investor confidence and position the company favorably against competitors in the pharmaceutical industry.

The study is ongoing, with further details available on the ClinicalTrials portal.